Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
08 juil. 2022 07h00 HE
|
Optinose, Inc.
Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from...
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
13 juin 2022 07h00 HE
|
Optinose, Inc.
First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients Physicians Diagnose Chronic Sinusitis 10 Times...
Optinose Announces Departure of Chief Financial Officer
03 juin 2022 07h00 HE
|
Optinose, Inc.
Michele Janis Appointed Acting Chief Financial Officer Anthony Krick Appointed Vice President & Chief Accounting Officer YARDLEY, Pa., June 03, 2022 (GLOBE NEWSWIRE) -- Optinose...
Optinose Announces Reporting Date for First Quarter 2022 Financial Results
05 mai 2022 17h00 HE
|
Optinose, Inc.
Conference Call and Webcast to be held May 12, 2022, at 8:00 a.m. Eastern Time YARDLEY, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients...
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
08 mars 2022 07h00 HE
|
Optinose, Inc.
Company reports fourth quarter and full year 2021 XHANCE net revenue of $22.5 million and $73.7 million Full year 2021 XHANCE prescriptions increased 28% compared to full year 2020 Company expects...
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
07 mars 2022 07h00 HE
|
Optinose, Inc.
XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug...
Optinose to Present at the Piper Sandler Virtual Healthcare Conference
23 nov. 2021 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 nov. 2021 16h30 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose Announces Closing of $46.0 Million Public Offering of Common Stock
18 nov. 2021 14h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Pricing of Public Offering of Common Stock
16 nov. 2021 08h02 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...